Detail akcie BioAtla Rg online

Business Summary: BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Bioatla Inc revenues was not reported. Net loss increased 16% to $123.5M. Higher net loss reflects Research and development expense - Balan increase of 33% to $98.3M (expense), Other income (expense) decrease from $10K (income) to $87K (expense), Stock-based Compensation in R&D increase of 1% to $5.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.74 to -$2.58.